Rimon Therapeutics Ltd. www.rimontherapeutics.com may@rimontherapeutics.com

Sector(s):  Biomaterials, Biotechnology

Specialties:  Biomaterials, Cardiovascular, Drug delivery

Key Contacts:

President: Michael H. May, PhD

Company Description:

Background:

Rimon Therapeutics commercializes advanced medical polymers to address unmet needs and large markets. By focusing on its core competencies in biomaterials science, pre-clinical validation, and product innovation, Rimon Therapeutics aims to develop and market novel medical devices in partnership with biotechnology, pharmaceutical and medical device companies.

Technologies:

Rimon's primary and unique focus is on Theramers®, or therapeutic polymers. These are advanced materials that have biological activity in and of themselves, without the delivery of pharmaceuticals or cells. Unlike polymeric drugs that are designed to be soluble, Theramers® are synthetic polymers that are intended to be exploited as solids (e.g., beads, scaffolds and coatings). Rimon is developing both degradable and non-degradable versions of its Theramers® and other "enabling" polymers. Rimon's three lead products are: a liquid dressing for chronic wounds (e.g., diabetic ulcers and bedsores), a unique polymer to treat dermal defects (e.g., wrinkles and acne scars) and a Theramer® that induces the development of new blood vessels for the treatment of ischemic tissue (e.g., skin grafts and chronic wounds) Discovery Stage: Various cardiovascular, ophthalmic, and wound healing product concepts, plus anti-microbial materials

See:

http://www.biotechontario.com/bp/organization.do?task=display&print=on&organizationNo=709